Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weiru Wang

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Journal of Medicinal Chemistry|May 27, 2016
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical DevelopmentJames F Blake, Michael Burkard, Jocelyn Chan, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2013
Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition propertiesJanet Gunzner-Toste, Guiling Zhao, Paul Bauer, et al.
Nature|October 16, 2015
RAF inhibitors that evade paradoxical MAPK pathway activationChao Zhang, Wayne Spevak, Ying Zhang, et al.
Nature|July 30, 2010
Diverse somatic mutation patterns and pathway alterations in human cancersZhengyan Kan, Bijay S Jaiswal, Jeremy Stinson, et al.
Journal of Medicinal Chemistry|March 2, 2026
Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12CMatthew L Landry, Sushant Malhotra, Maureen Beresini, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 2009
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agentDean R Artis, Jack J Lin, Chao Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2013
Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Xiaozhang Zheng, Kenneth W Bair, Paul Bauer, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityJames Tsai, John T Lee, Weiru Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 3, 2019
Disruption of IRE1α through its kinase domain attenuates multiple myelomaJonathan M Harnoss, Adrien Le Thomas, Anna Shemorry, et al.
Nature Genetics|November 18, 2014
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypesSteffen Durinck, Eric W Stawiski, Andrea Pavía-Jiménez, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Journal of Medicinal Chemistry|May 27, 2016
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical DevelopmentJames F Blake, Michael Burkard, Jocelyn Chan, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2013
Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition propertiesJanet Gunzner-Toste, Guiling Zhao, Paul Bauer, et al.
Nature|October 16, 2015
RAF inhibitors that evade paradoxical MAPK pathway activationChao Zhang, Wayne Spevak, Ying Zhang, et al.
Nature|July 30, 2010
Diverse somatic mutation patterns and pathway alterations in human cancersZhengyan Kan, Bijay S Jaiswal, Jeremy Stinson, et al.
Journal of Medicinal Chemistry|March 2, 2026
Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12CMatthew L Landry, Sushant Malhotra, Maureen Beresini, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 2009
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agentDean R Artis, Jack J Lin, Chao Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2013
Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Xiaozhang Zheng, Kenneth W Bair, Paul Bauer, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityJames Tsai, John T Lee, Weiru Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 3, 2019
Disruption of IRE1α through its kinase domain attenuates multiple myelomaJonathan M Harnoss, Adrien Le Thomas, Anna Shemorry, et al.
Nature Genetics|November 18, 2014
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypesSteffen Durinck, Eric W Stawiski, Andrea Pavía-Jiménez, et al.
Pageof 10